AR
YMAB

Advisory Research’s Y-mAbs Therapeutics YMAB Stock Holding History

Advisory Research’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-22,391
Closed -$584K – 354
2020
Q1 		$584K Sell
22,391
-11,560
-34% -$336K 0.04% 174
2019
Q4 		$1.06M Buy
+33,951
New +$1M 0.05% 182

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Advisory Research's YMAB Position: Q2 2020 in Review

Advisory Research sold out of Y-mAbs Therapeutics (YMAB) in Q2 2020, closing a stake of 22,391 shares — an estimated $584K sold.

Advisory Research first reported a position in YMAB in Q4 2019 and held it in 2 quarters. The position peaked at $1.06M in Q4 2019. 109 funds tracked by Wall St. Rank hold YMAB as of Q2 2020.

  • Advisory Research reported no remaining Y-mAbs Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Advisory Research sold 22,391 Y-mAbs Therapeutics shares in Q2 2020, an estimated $584K.
  • Advisory Research first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 2 quarters.
  • Advisory Research's Y-mAbs Therapeutics position peaked at $1.06M in Q4 2019.
  • 109 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2020.

Based on Advisory Research's 13F filing for Q2 2020, filed 13 Aug 2020.